AbbVie has secured FDA acceptance of a supplemental Biologics License Application (sBLA) for BOTOX Cosmetic targeting masseter muscle prominence—the lower-jaw aesthetic indication that has driven off-label demand for years. The filing signals formal regulatory review is underway.
Regulatory
AbbVie Wins FDA Review for BOTOX Jawline Indication
Supplemental BLA for masseter prominence moves forward, opening a new revenue stream for practices.
1-YEAR MOVE
ABBV
▲11.6%
| Ticker | Company | 1-year change |
|---|---|---|
| ABBV | AbbVie (Allergan Aesthetics) | +11.6% |
Masseter treatment has driven off-label demand for years; FDA approval removes prescriber liability and opens marketing pathways.
This is material for practice economics. Masseter treatment has been a high-volume, high-margin procedure in many medspas and cosmetic dermatology practices, typically requiring 20–50 units per side at premium pricing. FDA approval legitimizes the indication, removes prescriber liability, and opens reimbursement and marketing pathways currently unavailable for off-label use. Expect AbbVie to market aggressively once approved; practices should prepare for patient education and protocol refinement. The indication also raises the stakes for competing toxins seeking similar clearances.
Source: original report ↗
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/moJoin the owners who run ahead of the industry. Cancel anytime, one click.